TJ342B - Derivatives of 6-aryl pyrido Ä2,3-dÜ pyrimidines and naphthyridines pharmaceutical composition possess inhibiting effect of cellular proliferation pr ovoking protein tyrosine kinase and method of inhibiting cellular proliferation - Google Patents

Derivatives of 6-aryl pyrido Ä2,3-dÜ pyrimidines and naphthyridines pharmaceutical composition possess inhibiting effect of cellular proliferation pr ovoking protein tyrosine kinase and method of inhibiting cellular proliferation

Info

Publication number
TJ342B
TJ342B TJ97000469A TJ97000469A TJ342B TJ 342 B TJ342 B TJ 342B TJ 97000469 A TJ97000469 A TJ 97000469A TJ 97000469 A TJ97000469 A TJ 97000469A TJ 342 B TJ342 B TJ 342B
Authority
TJ
Tajikistan
Prior art keywords
cellular proliferation
inhibiting
naphthyridines
tyrosine kinase
protein tyrosine
Prior art date
Application number
TJ97000469A
Inventor
Clifton John Blankley
Annette Marian Doherty
James Marino Hamby
Robert Lee Panek
Mel Conrad Shroeder
Howard Daniel Hollis Owalter
Cleo Connolly
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/539,410 external-priority patent/US5733913A/en
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of TJ342B publication Critical patent/TJ342B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

6-Aryl naphthyridines are inhibitors of protein tyrosine kinase, and are thus useful in treating cellular proliferation mediated thereby. The compounds are especially useful in treating atherosclerosis, restenosis, psoriasis, as well as bacterial infections.
TJ97000469A 1994-11-14 1995-11-13 Derivatives of 6-aryl pyrido Ä2,3-dÜ pyrimidines and naphthyridines pharmaceutical composition possess inhibiting effect of cellular proliferation pr ovoking protein tyrosine kinase and method of inhibiting cellular proliferation TJ342B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33905194A 1994-11-14 1994-11-14
US08/539,410 US5733913A (en) 1994-11-14 1995-11-06 6-Aryl pyrido 2,3-d! pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation

Publications (1)

Publication Number Publication Date
TJ342B true TJ342B (en) 2002-10-06

Family

ID=26991470

Family Applications (1)

Application Number Title Priority Date Filing Date
TJ97000469A TJ342B (en) 1994-11-14 1995-11-13 Derivatives of 6-aryl pyrido Ä2,3-dÜ pyrimidines and naphthyridines pharmaceutical composition possess inhibiting effect of cellular proliferation pr ovoking protein tyrosine kinase and method of inhibiting cellular proliferation

Country Status (25)

Country Link
US (1) US5952342A (en)
EP (1) EP0790997B1 (en)
CN (1) CN1085666C (en)
AT (1) ATE190978T1 (en)
AU (1) AU711426B2 (en)
BG (1) BG63162B1 (en)
CZ (1) CZ286160B6 (en)
DE (1) DE69515898T2 (en)
DK (1) DK0790997T3 (en)
ES (1) ES2146782T3 (en)
FI (1) FI971953A7 (en)
GE (1) GEP20012444B (en)
GR (1) GR3033439T3 (en)
HU (1) HUT76853A (en)
IL (1) IL115970A (en)
MD (1) MD1861G2 (en)
MX (1) MX9702245A (en)
NO (1) NO308250B1 (en)
NZ (1) NZ296456A (en)
PL (1) PL181893B1 (en)
PT (1) PT790997E (en)
RU (1) RU2191188C2 (en)
SK (1) SK281724B6 (en)
TJ (1) TJ342B (en)
WO (1) WO1996015128A2 (en)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
ATE227283T1 (en) 1996-07-13 2002-11-15 Glaxo Group Ltd CONDENSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EP1806348A3 (en) * 1997-02-05 2008-01-02 Warner-Lambert Company LLC Pyrido [2, 3 -d] pyrimidines and 4-amino-primidines as inhibitors of cellular proliferation
US6498163B1 (en) 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
WO1998033798A2 (en) * 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
EP1003745B1 (en) * 1997-08-20 2004-12-29 Warner-Lambert Company Llc Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
EP1801112A1 (en) * 1998-05-26 2007-06-27 Warner-Lambert Company LLC Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
YU73300A (en) * 1998-05-26 2003-08-29 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydro-pyrimidines as inhibitors of cellular proliferation
GB9822450D0 (en) * 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
GB9914486D0 (en) 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB9917406D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
HUP0204141A3 (en) * 2000-01-25 2005-03-29 Warner Lambert Co Pyrido[2,3d]pyrimidine-2,7-diamine inhibitors, pharmaceutical compositions containing them and their use
ES2278778T3 (en) 2000-07-26 2007-08-16 Smithkline Beecham Plc AMINOPIPERIDIN QUINOLINAS AND ITS AZAISOSTERIC ANALOGS WITH ANTIBACTERIAL ACTIVITY.
US6518276B2 (en) * 2000-08-31 2003-02-11 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (II)
US6506749B2 (en) 2000-08-31 2003-01-14 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (I)
JP4141830B2 (en) * 2000-08-31 2008-08-27 エフ．ホフマン−ラ ロシュ アーゲー 7-Oxo-pyridopyrimidines as inhibitors of cell proliferation
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
JP2004521118A (en) * 2001-01-19 2004-07-15 スミスクライン・ビーチャム・コーポレイション New compounds and their use
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
CN100376571C (en) * 2001-02-12 2008-03-26 霍夫曼-拉罗奇有限公司 6-substituted pyridopyrimidines
WO2002090360A1 (en) * 2001-05-10 2002-11-14 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
WO2003000011A2 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
AP1767A (en) 2002-01-22 2007-08-13 Warner Lambert Co 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones.
JP4508650B2 (en) 2002-01-29 2010-07-21 グラクソ グループ リミテッド Aminopiperidine compound, process for producing the compound and pharmaceutical composition containing the compound
TW200406410A (en) 2002-01-29 2004-05-01 Glaxo Group Ltd Compounds
EP1481678A4 (en) * 2002-03-05 2009-12-30 Eisai R&D Man Co Ltd Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor
PA8577501A1 (en) 2002-07-25 2004-02-07 Warner Lambert Co KINASE INHIBITORS
ES2293064T3 (en) 2002-08-06 2008-03-16 F. Hoffmann-La Roche Ag 6-ALCOXI-PIRIDO-PIRIMIDINAS AS INHIBITORS OF THE P-38 MAP QUINASA.
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
TW200502236A (en) 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
RU2263146C2 (en) * 2003-07-10 2005-10-27 Михаил Викторович Разуменко Method for preparing bacteriophages binding specifically with target-cells and designated for therapeutic aims
BRPI0412516A (en) * 2003-07-11 2006-09-19 Warner Lambert Co isethionate salt of a selective cdk4 inhibitor
BRPI0416030A (en) 2003-11-13 2007-01-02 Hoffmann La Roche hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
EP2233174B1 (en) 2004-01-21 2016-07-20 Emory University Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
WO2005090344A1 (en) * 2004-03-15 2005-09-29 F. Hoffmann-La Roche Ag Novel dichloro-phenyl-pyrido [2,3-d] pyrimidine derivates, their manufacture and use as pharmaceutical agents
FR2873118B1 (en) 2004-07-15 2007-11-23 Sanofi Synthelabo PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS
EP1794160A1 (en) * 2004-09-21 2007-06-13 F.Hoffmann-La Roche Ag 6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as proteine kinase inhibitors
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CA2584507C (en) * 2004-10-20 2016-04-26 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
CA2593718A1 (en) * 2004-12-31 2007-05-31 Gpc Biotech Ag Napthyridine compounds as rock inhibitors
FR2887882B1 (en) 2005-07-01 2007-09-07 Sanofi Aventis Sa PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
EP2314295B1 (en) 2005-07-29 2015-01-28 Resverlogix, Inc Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
DE602006017281D1 (en) * 2005-08-09 2010-11-11 Irm Llc COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
US20070082920A1 (en) * 2005-10-06 2007-04-12 Yongsheng Song NAD+-dependent DNA ligase inhibitors
RU2445315C2 (en) * 2005-11-22 2012-03-20 Кудос Фармасьютиклз Лимитед PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AND USE THEREOF AS mTOR INHIBITORS
FR2896246B1 (en) 2006-01-13 2008-08-15 Sanofi Aventis Sa PYRIDO-PYRIMIDONE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
CN101374840B (en) 2006-01-31 2011-09-28 霍夫曼-拉罗奇有限公司 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
GEP20115306B (en) 2006-09-15 2011-10-10 Pfizer Prod Inc
CA2668731A1 (en) * 2006-11-09 2008-05-15 Tobias Gabriel Kinase inhibitors and methods for using the same
FR2910813B1 (en) 2006-12-28 2009-02-06 Sanofi Aventis Sa NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA
CA2676984C (en) 2007-02-01 2015-03-17 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
WO2008104473A2 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Pyrazolopyriidine derivatives and their use as kinase inhibitors
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
AU2010204106B2 (en) 2009-01-08 2014-05-08 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
WO2010106436A2 (en) 2009-03-18 2010-09-23 Resverlogix Corp. Novel anti-inflammatory agents
AU2010239266B2 (en) 2009-04-22 2015-01-22 Resverlogix Corp. Novel anti-inflammatory agents
ES2347630B1 (en) * 2009-04-29 2011-09-08 Universitat Ramon Llull SYNTHESIS AND USES OF 4-CIANOPENTANOATOS AND 4-CIANOPENTENOATS SUBSTITUTED.
GB0922589D0 (en) * 2009-12-23 2010-02-10 Almac Discovery Ltd Pharmaceutical compounds
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
CA2851996C (en) 2011-11-01 2020-01-07 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
HRP20170430T1 (en) 2012-06-13 2017-06-16 Incyte Holdings Corporation Substituted tricyclic compounds as fgfr inhibitors
LT2872491T (en) 2012-07-11 2021-08-25 Blueprint Medicines Corporation FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
CA2907243C (en) 2013-03-15 2021-12-28 Celgene Avilomics Research, Inc. Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
WO2014144737A1 (en) * 2013-03-15 2014-09-18 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
AR095464A1 (en) 2013-03-15 2015-10-21 Celgene Avilomics Res Inc HETEROARILO COMPOUNDS AND USES OF THE SAME
PL2986610T4 (en) 2013-04-19 2019-06-28 Incyte Holdings Corporation Bicyclic heterocycles as fgfr inhibitors
RU2704112C2 (en) 2013-10-25 2019-10-24 Блюпринт Медсинс Корпорейшн Fibroblast growth factor receptor inhibitors
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MY197720A (en) 2015-02-20 2023-07-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
WO2016147053A1 (en) 2015-03-13 2016-09-22 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
SG10201810057UA (en) * 2015-04-14 2018-12-28 Eisai R&D Man Co Ltd Crystalline fgfr4 inhibitor compound and uses thereof
CN104774183B (en) * 2015-04-24 2017-10-13 合肥新诺华生物科技有限公司 A kind of auspicious relax of formoxyl cuts down the preparation method of spit of fland calcium intermediate
WO2018023081A1 (en) * 2016-07-29 2018-02-01 Achaogen, Inc. 6-phenylpyrido[2,3-d]pyrimidine compounds as antibacterial agents
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
TWI905079B (en) 2018-04-23 2025-11-21 日商千紙鶴治療公司 Growth inhibitor
BR112020022392A2 (en) 2018-05-04 2021-02-02 Incyte Corporation solid forms of a fgfr inhibitor and processes for preparing them
JP7568512B2 (en) 2018-05-04 2024-10-16 インサイト・コーポレイション Salt of FGFR inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2022550539A (en) * 2019-10-01 2022-12-02 ゴールドフィンチ バイオ，インク． Substitutional 1,6-naphthyridine inhibitors of CDK5
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP7675711B2 (en) 2019-10-14 2025-05-13 インサイト・コーポレイション Bicyclic heterocycles as FGFR inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
PE20221504A1 (en) 2019-12-04 2022-09-30 Incyte Corp DERIVATIVES OF AN FGFR INHIBITOR
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
AR126102A1 (en) 2021-06-09 2023-09-13 Incyte Corp TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171218A (en) * 1967-11-09 1969-11-19 Parke Davis & Co New Heterocyclic Amine Compounds and Methods for their Production
US3639401A (en) * 1969-07-28 1972-02-01 Parke Davis & Co 6-aryl-2 7-bis((trialkylsilyl)amino)pyrido (2 3-d)pyrimidine compounds
US4271164A (en) * 1979-04-16 1981-06-02 Warner-Lambert Company 6-Substituted-arylpyrido[2,3-d]pyrimidin-7-amines and derivatives
US4771054A (en) * 1985-01-23 1988-09-13 Warner-Lambert Company Antibacterial agents
US4771057A (en) * 1986-02-03 1988-09-13 University Of Alberta Reduced pyridyl derivatives with cardiovascular regulating properties
DK172753B1 (en) * 1988-05-25 1999-06-28 Lilly Co Eli N- (5,6,7,8-tetrahydropyrido [2,3-d] pyrimidin-6-yl-alkanoyl) -glutamic acid derivatives, their use, pharmaceutical preparations
DE4131029A1 (en) * 1991-09-18 1993-07-29 Basf Ag SUBSTITUTED PYRIDO (2,3-D) PYRIMIDINE AS ANTIDOTS

Also Published As

Publication number Publication date
MD1861F2 (en) 2002-02-28
NO308250B1 (en) 2000-08-21
US5952342A (en) 1999-09-14
PL320169A1 (en) 1997-09-15
NZ296456A (en) 1999-09-29
DE69515898D1 (en) 2000-04-27
NO972198L (en) 1997-05-13
IL115970A0 (en) 1996-01-31
FI971953L (en) 1997-05-12
AU4107896A (en) 1996-06-06
MD970187A (en) 1999-02-28
WO1996015128A3 (en) 1996-07-11
PL181893B1 (en) 2001-10-31
ATE190978T1 (en) 2000-04-15
PT790997E (en) 2000-06-30
BG101326A (en) 1998-04-30
EP0790997B1 (en) 2000-03-22
CZ139097A3 (en) 1998-02-18
SK60997A3 (en) 1998-05-06
MD1861G2 (en) 2002-09-30
DE69515898T2 (en) 2000-08-17
BG63162B1 (en) 2001-05-31
MX9702245A (en) 1997-06-28
CN1085666C (en) 2002-05-29
WO1996015128A2 (en) 1996-05-23
GEP20012444B (en) 2001-05-25
CN1169726A (en) 1998-01-07
SK281724B6 (en) 2001-07-10
GR3033439T3 (en) 2000-09-29
CZ286160B6 (en) 2000-01-12
ES2146782T3 (en) 2000-08-16
HUT76853A (en) 1997-12-29
EP0790997A2 (en) 1997-08-27
RU2191188C2 (en) 2002-10-20
AU711426B2 (en) 1999-10-14
NO972198D0 (en) 1997-05-13
DK0790997T3 (en) 2000-08-21
FI971953A0 (en) 1997-05-07
FI971953A7 (en) 1997-05-12
IL115970A (en) 1999-06-20

Similar Documents

Publication Publication Date Title
TJ342B (en) Derivatives of 6-aryl pyrido Ä2,3-dÜ pyrimidines and naphthyridines pharmaceutical composition possess inhibiting effect of cellular proliferation pr ovoking protein tyrosine kinase and method of inhibiting cellular proliferation
IL117923A0 (en) Pyrido [2,3-d] pyrimidine derivatives and pharmaceutical compositions containing them
CA2291222A1 (en) Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
AP9901435A0 (en) Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors.
CA2400554A1 (en) Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
MY141144A (en) 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
NO984199D0 (en) New N-7-heterocyclylpyrrolo [2,3-D] pyridines and their use
PL344248A1 (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
PL327735A1 (en) Novel substituted derivatives of imidazole
CA2315647A1 (en) Inhibition of p38 kinase activity using aryl and heteroaryl substituted heterocyclic ureas
BRPI0412993A (en) akt activity inhibitors
TR199900049T2 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors.
AU1783201A (en) 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
AU1781601A (en) 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
BG105003A (en) Combinations of protein farnesyltransfer and hmg coa reductase inhibitors and their use to treat cancer
CO4920227A1 (en) HISTIDINA-N-BENCIL GLICINAMIDA SUBSTITUTED WITH CYCLLOALKYL.
DE59712297D1 (en) 3-ALKYLIMIDAZOPYRIDINE